New Delhi: Nov 27, 2010
Women's organisations and health experts, including a member of the Population Council of India, have impressed upon the Drug Technical Advisory Board (DTAB) to disallow the use of Depot medroxyprogesterone acetate (DMPA) – an injectable contraceptive used in the family planning programme. The DMPA, a progestogen-only contraceptive injected every 3 months, was licensed by the Drugs Controller of India in the 1990s. An intervention petition filed in the matter led to the DTAB restricting its use to private market.The approval itself was based on the manufacturer Max Pharma carrying out post-marketing studies as this injection was not properly researched in India.
Read more
Women's organisations and health experts, including a member of the Population Council of India, have impressed upon the Drug Technical Advisory Board (DTAB) to disallow the use of Depot medroxyprogesterone acetate (DMPA) – an injectable contraceptive used in the family planning programme. The DMPA, a progestogen-only contraceptive injected every 3 months, was licensed by the Drugs Controller of India in the 1990s. An intervention petition filed in the matter led to the DTAB restricting its use to private market.The approval itself was based on the manufacturer Max Pharma carrying out post-marketing studies as this injection was not properly researched in India.
Read more
RSS Feed
